IP Library Patent Application 18762014
Patent Application
App. No. 18/762,014

DESIGN AND FABRICATION OF PATIENT-SPECIFIC STIMULI-RESPONSIVE CARDIOVASCULAR STENTS FOR CORONARY ARTERY SPASM TREATMENT TO ELIMINATE POST-SURGICAL INTERVENTIONS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
18/762,014
Abstract

Example systems, methods, and apparatus are disclosed herein for a design and fabrication of patient-specific stimuli-responsive cardiovascular stents for coronary artery spasm treatment to eliminate post-surgical interventions. The stimuli-responsive material may be a magnetically-induced shape memory nanoparticle such as Hematite dispersed in PLA. Such Hematite may be at a concentration of 10 wt % to 20 wt %.

Claims (32)

1 . A patient-specific stimuli-responsive cardiovascular stent for coronary artery spasm treatment to eliminate post-surgical interventions comprising a magnetic nanoparticle configured to enable magnetically induced shape memory effects.

2 . The stent of claim 1 , wherein the magnetic nanoparticle comprises Hematite (α-Fe 2 O 3 ).

3 . The stent of claim 2 , wherein the concentration of Hematite is at least 10 wt %.

4 . The stent of claim 2 , wherein the concentration of Hematite is at least 15 wt %.

5 . The stent of claim 2 , wherein the concentration of Hematite is at least 20 wt %.

6 . The stent of claim 1 , wherein the stent is configured to have a desired magnetically induced shape memory position for a coronary artery spasm treatment.

7 . A method of fabricating a patient-specific stimuli-responsive cardiovascular stent for coronary artery spasm treatment to eliminate post-surgical interventions comprising:

dissolving PLA in dichloromethane (DCM) using a mechanical mixer;

adding a concentration of magnetic sensitive α-Fe 2 O 3 nanoparticles to the PLA/DCM solution;

mechanically stirring the solution for 4 hours at a speed of between 1300-1500 rpm;

heating the solution to 40° C. with continuous stirring to remove the solvent (DCM) from the mixture;

laying the PLA/α-Fe 2 O 3 nanocomposites on a flat surface to remove the entrapped solvent; and

obtaining nanocomposites in film form.

8 . The method of claim 7 , further comprising:

forming a stent by additive manufacturing using the nanocomposites.

9 . The method of claim 8 , wherein the concentration of magnetic sensitive Hematite (α-Fe2O3) is 10 wt %.

10 . The method of claim 8 , wherein the concentration of magnetic sensitive Hematite (α-Fe 2 O3) is 15 wt %.

11 . The method of claim 8 , wherein the concentration of magnetic sensitive Hematite (α-Fe 2 O 3 ) is 20 wt %.

12 . The method of claim 8 , further comprising:

configuring the stent to have a desired magnetically induced shape memory position.

13 . A method of using a patient-specific stimuli-responsive cardiovascular stent for coronary artery spasm treatment to eliminate post-surgical interventions comprising:

determining a desired configuration of the stimuli-responsive cardiovascular stent based on a physiology of a patient; and

producing a stimuli-responsive cardiovascular stent based on the desired configuration.

14 . The method of claim 13 , wherein the cardiovascular stent is produced by a process of additive manufacturing.

15 . The method of claim 14 , wherein the process of additive manufacturing occurs within the vicinity of the patient.

16 . The method of claim 13 , wherein the cardiovascular stent comprises a PLA/α-Fe 2 O 3 nanocomposite.

17 . The method of claim 16 , wherein the concentration of α-Fe 2 O 3 in the PLA/α-Fe 2 O 3 nanocomposite is at least 10 wt %.

18 . The method of claim 16 , wherein the concentration of α-Fe 2 O 3 in the PLA/α-Fe 2 O 3 nanocomposite is at least 15 wt %.

19 . The method of claim 16 , wherein the concentration of α-Fe 2 O 3 in the PLA/α-Fe 2 O 3 nanocomposite is at least 20 wt %.

20 . The method of claim 13 , further comprising:

providing the cardiovascular stent to the patient; and

actuating the cardiovascular stent by applying a magnetic field near the cardiovascular stent.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 17, 2025
From: QATAR FOUNDATION FOR EDUCATION, SCIENCE & COMMUNITY DEVELOPMENT
To: HAMAD BIN KHALIFA UNIVERSITY
Reel/Frame 069936/0656 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 8, 2024
From: KOC, MUAMMER; RASHID, ANS AL
To: QATAR FOUNDATION FOR EDUCATION, SCIENCE AND COMMUNITY DEVELOPMENT
Reel/Frame 067927/0486 →